Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm - Boston Scientific ( NYSE:BSX )
In December 2023, Boston Scientific Corporation ( NYSE: BSX ) initiated the AVANT GUARD trial to evaluate the safety and effectiveness of the FARAPULSE Pulsed Field Ablation ( PFA ) System as a first-line treatment for persistent atrial fibrillation ( AF ) .
https://www.benzinga.com/general/biotech/24/10/41505607/boston-scientific-pauses-enrollment-in-farapulse-study-in-drug-naive-patients-with-irregular-hear